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The NF-kB inducing kinase (NIK) regulates the non-
canonical NF-kB pathway downstream of important
clinical targets including BAFF, RANKL, and LTb.
Despite numerous genetic studies associating dys-
regulation of this pathwaywith autoimmune diseases
and hematological cancers, detailed molecular char-
acterization of this central signaling node has been
lacking. We undertook a systematic cloning and
expression effort to generate soluble, well-behaved
proteins encompassing the kinase domains of
human and murine NIK. Structures of the apo NIK
kinase domain from both species reveal an active-
like conformation in the absence of phosphorylation.
ATP consumption and peptide phosphorylation
assays confirm that phosphorylation of NIK does
not increase enzymatic activity. Structures of murine
NIK bound to inhibitors possessing two different
chemotypes reveal conformational flexibility in the
gatekeeper residue controlling access to a hydro-
phobic pocket. Finally, a single amino acid difference
affects the ability of some inhibitors to bind murine
and human NIK with the same affinity.
INTRODUCTION
The NF-kB transcription factors are critical mediators of in-
flammatory and immune responses. NF-kB is activated by
extracellular stimuli including pro-inflammatory cytokines, mito-
gens, DNA-damaging agents, and microbial agents (Baltimore,
2011). Two pathways of NF-kB activation utilize different intra-
cellular signaling cascades. The canonical NF-kB pathway is
activated downstream of multiple pro-inflammatory receptors
such as the T cell receptor, B cell receptor, Toll-like receptor,1704 Structure 20, 1704–1714, October 10, 2012 ª2012 Elsevier Ltdand TNF receptor. Signaling in this axis is mediated by the
trimeric IkB kinase (IKK) complex (IKKa, IKKb, and IKKg) that
phosphorylates IkBa proteins and ultimately leads to the pro-
cessing of inactive NF-kB1 (p105) precursor to its active p50
that can pair with another of the Rel homology domain-contain-
ing proteins to generate a heterodimeric transcription factor
(Perkins, 2012).
The non-canonical NF-kB pathway is activated downstream
of a subset of the TNF superfamily of receptors including BR3,
CD40, TWEAK, LT-bR, and RANK (Razani et al., 2011; Sun,
2012). These receptors primarily regulate lymphoid organogen-
esis, B cell proliferation and survival, and osteoclastogenesis.
Intracellular signal transduction via the noncanonical NF-kB
pathway requires the NF-kB inducing kinase (NIK). NIK is
a Serine/Threonine kinase also known as MAP3K14 (Malinin
et al., 1997). NIK belongs to the STE branch of the kinome and
is a non-RD kinase (Johnson et al., 1996) that lacks the con-
served arginine residue prior to the catalytic base. Although
characterization of NIK activity has been limited by difficulty in
generating soluble, well-behaved recombinant protein, studies
in transfected cells suggested Thr559 is important for NIK func-
tion as mutation of this residue to alanine results in decreased
phosphorylation of downstream targets in the NF-kB signaling
pathway (Lin et al., 1998). While NIK is widely expressed, the
level of NIK protein is very low in the absence of an exogenous
signal due to constitutive ubiquitin-mediated proteasomal deg-
radation following recruitment to a TRAF2/TRAF3/cIAP complex
(Varfolomeev et al., 2007; Zarnegar et al., 2008a, 2008b). Activa-
tion of the noncanonical NF-kB pathway results in proteasomal
removal of cIAPs and sequestration of TRAFs with concomitant
stabilization of NIK protein levels (Sun, 2012). This allows accu-
mulation of NIK protein that then phosphorylates the regulatory
kinase IKKa at Ser 176 (Ling et al., 1998). This phosphorylation
event activates IKKa and ultimately leads to the processing of
the inactive NF-kB2 (p100) precursor to its active p52 form.
The p52 then pairs with RelB to form a heterodimeric transcrip-
tion factor that translocates to the nucleus to activate gene tran-
scription (Perkins, 2012).All rights reserved
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Structure of the NF-kB Inducing KinaseDysregulation of both the canonical and noncanonical NF-kB
pathways and of NIK in particular is associated with autoimmune
disorders and hematologic malignancies (Demchenko et al.,
2010; Hymowitz and Wertz, 2010; Lim et al., 2012; Perkins,
2012; Thu andRichmond, 2010; Yamagishi et al., 2012). Inappro-
priate accumulation of NIK, due to loss of the TRAF-binding
sequence as a result of cleavage byMALT fusion proteins (Rose-
beck et al., 2011) or other mechanisms (Yamagishi et al., 2012),
is associated with the development multiple myeloma. Interven-
tion in the noncanonical pathway has been shown to be benefi-
cial in treating disease. For instance, inhibition of BAFF and
CD40L signaling is efficacious in the treatment of autoimmune
diseases (Navarra et al., 2011; Sidiropoulos and Boumpas,
2004). Blockade of RANKL is approved for osteoporosis and
also shows efficacy in preventing bone erosions in rheumatoid
arthritis (Dempster et al., 2012). Similarly, mice deficient in NIK
are protected from bone destruction in models of rheumatoid
arthritis (Aya et al., 2005). Thus, inhibition of NIK activity may
be of clinical benefit in several human diseases.
To better understand the structure and enzymatic activity of
NIK, we produced soluble recombinant NIK protein and deter-
mined the structures of the human (hNIK) and murine NIK
(mNIK) kinase domains alone and bound to small molecule
inhibitors. These structures show the NIK kinase domain has
an active-like conformation in the absence of phosphorylation
and displays conformational variability in the phosphate-coordi-
nating loop (P loop). The structures of mNIK bound to two
classes of active site inhibitors reveal a narrow nucleotide-
binding site. Biochemical assays show that phosphorylation of
NIK catalytic domain is not required for enzymatic activity.
Comparison of the activity of human and murine NIK reveals
the role of sequence differences on inhibitor potency. Collec-
tively this work elucidates the molecular basis of NIK kinase
activity and inhibition.
RESULTS
To express soluble, folded recombinant NIK protein, we under-
took a systematic approach in which sequential sets of con-
structs were produced to answer specific questions. Sequence
analysis indicated the presence of a protein kinase domain in the
middle third of the NIK protein. The N-terminal region has been
shown to contain a TRAF-binding motif (residues 78h–84h)
essential for regulation of NIK protein levels and a nuclear local-
ization signal (residues 136h –143h) (Figure 1A). The C-terminal
region is important for interaction with macromolecular sub-
strates (Ling et al., 1998). Thus, for the first set (‘‘wave’’) of
constructs, efforts focused on production of soluble kinase
domain expected to span residues 375h–655h (Figure 1B). Two
N-termini (327h and 377h) and two C-termini (Arg 673h, and
Asp 947h) were used. Several point mutations intended to reduce
kinase activity (D515hN, K429hM, T559hA) were generated as
well as a point mutation (T559hD) expected to mimic phosphor-
ylation of the activation loop. Longer constructs including the
C-terminal region (318h–947h) were generated for characteriza-
tion in enzymatic assays (see Table S1 available online). Con-
structs were tested for expression of soluble recombinant
protein at small scale. Constructs predicted to result in expres-
sion of at least 1 mg of soluble protein per liter of cell culture pro-Structure 20, 1704–1gressed to the 1–10 l scale. Recombinant proteins were purified
using Ni2+-affinity and conventional chromatography and were
characterized by mass spectrometry and dynamic light scat-
tering prior to crystallization trials. If protein yields permitted,
approximately 1200 crystallization conditions were tested per
construct.
This effort revealed that constructs encoding NIK fragments
starting at residue 377h did not generate soluble protein. How-
ever, longer constructs starting at 327h could produce soluble
enzyme when expressed in insect cells but not when expressed
in Escherichia coli (Table S1). The longer constructs include
a region encompassing residues 327h–375h, which is conserved
in NIK across species but is not part of the Pfam definition of
a kinase domain. Inclusion of the inactivating D515hN and
K429hM mutations, or the phosphomimetic T559hD mutation,
did not improve expression or solution properties of recombinant
NIK kinase domain.
A second set of forty-seven constructs included sampling of
six different N- and four different C-termini of murine and human
NIK (Table S1). The conclusion from these constructs was that
yields of recombinant murine NIK protein tended to be greater
than human NIK protein for the same volume of insect cell
culture. In addition, mNIK behaved better in purification, and
mNIK crystals were more robust and reproducible than hNIK
crystals. Thus, crystallization efforts largely focused on mNIK
constructs.
Structure of the apo Murine NIK Kinase Domain Reveals
an Active-like Conformation
Protein expressed from a construct encompassing the mNIK
kinase domain 329m–675m (327h–673h) crystallized and dif-
fracted to a resolution of 2.15 A˚ (Figure 2; Table 1). The resulting
structure shows the NIK kinase domain possesses the bilobed
architecture typical of protein kinases with an N-terminal pre-
dominantly beta-sheet lobe and a C-terminal helical lobe with
several unique features (Figure 2A). The conserved N-terminal
region (residues 334m–365m) preceding the canonical kinase
domain forms a helix-strand-helix motif. The initial helix (residues
334m–342m) extends away from the rest of the structure medi-
ating crystal-packing interactions by contacting the activation
loop and C-terminal lobe of an adjacent molecule. The strand
(residues 345m–350m) and second helix (residues 351m–363m)
closely associate with the kinase domain N-lobe, with the strand
participating in a six-strand b sheet and the helix packed against
the catalytically important ‘‘aC’’ helix (Figure 2B). The intimate
nature of these interactions is consistent with the observation
that expression of constructs starting at residue 377h did not
result in the production of soluble protein. The Ser/Thr rich
loop (363m-377m) connecting this region to the canonical kinase
domain is divergent between murine and human NIK and is
largely disordered. The conserved C-terminal residues (657m–
675m) following the minimal kinase domain pack against the
C-lobe in an extended conformation.
The nucleotide-binding site at the juncture of the N- and
C-lobes is partly occupied by the side chain of the ‘‘gatekeeper’’
residue Met 471m and the side chain of Arg 410m from the P loop
(Figure 2C). The guanidinium group of Arg 410m is positioned
approximately where the adenosine moiety would bind. There
is a small channel between Met 471m and Asp536m from the714, October 10, 2012 ª2012 Elsevier Ltd All rights reserved 1705
AB
Figure 1. Domain Structure of NIK Kinase
(A) Schematic diagram of humanNIK. Human andmurine NIK numbering differs by two amino acids.We indicatemurine and human numbering with a superscript
‘‘m’’ and ‘‘h,’’ respectively. The N-terminal region of NIK includes the TRAF3 binding site (residues 78h–84h, shown as a gray oval) and the nuclear localization
signal (residues 136h–143h, shown as a lavender oval). The core kinase domain is shown as a light blue rectangle flanked by red and blue rectangles indicating
N- and C-terminal sequences (327h–375h and 655h–675 h, respectively) that are conserved in NIK from multiple species, but divergent from other Serine/
Threonine kinases.
(B) Alignment ofmurine and humanNIK kinase domains to the core kinase region of PKA (residues 40–293). The conserved additions to the NIK kinase domain are
colored as in (A). The P loop is orange and the V408m/L406h difference is underlined. The gatekeeper residue 469h (underlined) and the hinge region is green.
Conserved kinase features are highlighted in lavender, while T559h is shown in light blue. The phosphothreonine in PKA (Thr 197) is shown in bold. Secondary
structure elements present in Apo mNIK are shown as lavender cylinders (helices) and green arrows (beta strands). Additional information on expression
constructs is found in Table S1.
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Figure 2. Structure of Apo NIK Kinase
Domain
(A) Structure of murine NIK kinase colored as in
Figure 1B.
(B) Close-up of the hydrophobic interactionsmade
by the residues 345m–363m with the aC helix.
(C) Final 2Fo-Fc (blue, 1s) and Fo-Fc (green, 4s)
electron density map shows the nucleotide-
binding site is unoccupied except for the side
chain of Arg 410m.
(D) Superposition of the active-like conformation
of PKA (taupe, PDB code 1ATP) and apo mNIK
colored as in (A) showing the apo mNIK confor-
mation has features of an active kinase. Residues
of interest are shown as sticks including the salt
bridge formed in PKA between the phospho-
threonine Thr 197 and the Arg 165 from the HRD
motif. TheCa atomof Phe of theGxGxFmotif from
both the structures is shown with a sphere as the
Ca atom of Gly 516m.
(E) Structure of human NIK kinase at 2.9 A˚ (green)
superimposed on mNIK kinase colored as in (A)
showing the similarity in the mNIK and hNIK
structures. Additional information on crystal
packing is included in Figure S1.
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Structure of the NF-kB Inducing KinaseDFGmotif that connects to a solvent filled ‘‘back pocket’’ behind
Met 471m. The absence of a visible cleft between the N- and
C-lobes in the NIK structure suggests that side chain rearrange-
ment or repositioning of the N-lobe relative to the C-lobe might
be necessary to permit nucleotide or inhibitor binding.
The N-terminal portion of the ‘‘glycine-rich’’ or P loop pre-
ceding the GxGxF motif lacks regular secondary structure in
contrast to most kinases that typically have a beta strand at
this position. The irregular conformation of the P loop may be
due in part to crystal-packing interactions with the N-terminal
lobe of an adjoining kinase (Figure S1A). In addition, residues
404m–409m in the P loop prior to the GxGxF motif have poor
electron density, suggesting that they are either mobile or exhibit
static disorder.
The activation loop is ordered in one of the two copies of mNIK
in the crystallographic asymmetric unit (Figures 2A and 2D). One
residue of particular interest is Thr 561m as mutation of this
residue to alanine in the context of human NIK (559h) has been
reported to reduce NIK activity (Lin et al., 1998). In this structure,
the side chain of Thr 561m is oriented toward the nucleotide-Structure 20, 1704–1714, October 10, 2012 ªbinding site and makes a hydrogen
bond with Asp 517m. This Asp is the
catalytic base of the kinase found in
the typical ‘‘HRD’’ motif that in NIK
is His515m–Gly516m–Asp517m (‘‘HGD’’).
Phosphorylation of Thr 561m (559h) in
NIK would likely be incompatible with
this conformation due to both steric and
electrostatic repulsion from Asp 517m.
Notably, this stretch of the activation
loop is relatively conserved and a similar
conformation is seen in diverse kinases
such as PKA (Knighton et al., 1991) and
PKC-theta (Xu et al., 2004) (Figure 2D).Despite the largely closed nucleotide-binding site, compar-
ison to the well-studied structure of protein kinase A reveals
the apo NIK kinase domain adopts a structure that is very close
to a catalytically active conformation (Figure 2D). In particular,
the DFG motif (residues 536m–538m) is in the ‘‘in’’ orientation
with Asp536m positioned to productively interact with Mg2+
and ATP. The Glu442m–Lys431m salt bridge is present and
orients the aC helix so that the enzyme is primed to bind and
process ATP. The activation loop traverses away from the ATP
binding site and is folded in an active-like conformation compe-
tent for substrate binding. The only features inconsistent with
a typical active kinase structure are the presence of the side
chain of Arg410m in the adenosine-binding site and the irregular
conformation of the P loop.
Structures of Murine and Human NIK Kinase Domains
Are Very Similar
To see whether any significant structural differences exist
between the human and murine NIK kinase, we crystallized
hNIK 308h–673h and determined the structure of the kinase2012 Elsevier Ltd All rights reserved 1707
Table 1. Data Collection and Refinement Statistics
Data Collection Apo mNIK Apo hNIK mNIK-Cmp1 mNIK-Cmp2 mNIK V408mL-Cmp3
Beamline ALS 5.0.1 SSRL 11-1 SSRL 7-1 ALS 5.0.1 SSRL 7-1
Space Group P43 P212121 P43 C2221 C2221
Unit cell dimensions (A˚) a = 142.2 a = 45.7 a = 143.1 a = 74.8 a = 74.4
c = 45.1 b = 145.9 c = 230.8 c = 45.2 b = 135.6 b = 135.3
c = 64.9 c = 64.3
Resolution Range (A˚) 50–2.15 30–2.9 50–2.50 50–1.64 40–2.5
Coverage (%) 99.6 (100) 100 (100) 99.6 (100) 96.7 (89.4) 99.3 (93.3)
Unique reflections 49462 35489 32116 39429 11486
Multiplicity 3.9 7.3 3.7 7.3 6.8
No. mol/asu 2 4 2 1 1
<I > / < sI > 19.9 (2.3) 21.8(3.6) 18.6 (2.0) 36.4 (4.3) 15.6 (1.8)
Rmerge (%) 6.9 (58.4) 9.8 (61.0) 6.8 (59.8) 5.3 (34.9) 11.9 (61.9)
Refinement
PDB accession code 4G3C 4G3D 4G3E 4G3F 4G3G
Resolution range (A˚) 50–2.15 30–2.9 50–2.5 50–1.64 40–2.5
R, Rfree (%) 18.6, 22.6 20.3, 26.6 18.9, 24.1 17.7, 20.8 19.6, 25.2
No. atoms 5227 9346 5094 2732 2424
RMSD bonds (A˚) 0.007 0.006 0.007 0.006 0.007
RMDS bond angles () 1.10 1.04 1.22 1.12 1.20
Ramachandran plot:
allowed, generously allowed,
and disallowed regions (%)
98.9, 0.9, 0.2 98.9, 0.6, 0.5 99.2, 0.6, 0.2 98.8, 0.8, 0.4 98.4, 1.2, 0.4
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Structure of the NF-kB Inducing Kinasedomain at 2.9 A˚ resolution (Table 1). The amino acid sequences
of the human and murine NIK kinase domains are 87% identical
(Figure 1B) and the structures are correspondingly similar with
a pairwise root mean square deviation (rmsd) of 0.55–0.58 A˚2
on Ca atoms (Figure 2E). Key structural features such as the
salt bridge between Glu440h and Lys429h and the conformation
of Thr559h are alike in the mNIK and hNIK structures. Most of the
amino acid sequence differences between the two species are
remote from the catalytic site with many of them in the non-
conserved loop encompassing residues 363h-375h. The only
sequence discordance within 4.2 A˚ of the expected ATP binding
site is Leu 406h in humanNIK that is a Valine (408m) inmurine NIK.
The P loop has the same conformation in the apo hNIK structure
as in apo mNIK likely due to the similarity of the crystal-packing
contacts in the crystals of murine and human NIK (Figure S1).
The activation loop is ordered in two of the four independent
copies of hNIK in the asymmetric unit. The conformation of the
distal solvent exposed region of the activation loop differs signif-
icantly between the two hNIK chains and frommNIK, suggesting
that the activation loop structure varies in the absence of bound
substrate or inhibitor. With the exception of the activation loop,
the four hNIK molecules are very similar with a pairwise rmsd
of 0.28–0.39 A˚2 on backbone Ca atoms.
Despite crystallizing in a different space group and under
distinct conditions, the crystal packing in the mNIK and hNIK
kinase structures is closely related in P43 ab plane (Figure S1). In
the orthorhombic human NIK crystals, a four-fold non-crystallo-
graphic symmetry axis replaces the four-fold crystallographic
symmetry axis in the P43 mNIK crystals. This crystal packing
results in a ring-like arrangement of kinase molecules with the1708 Structure 20, 1704–1714, October 10, 2012 ª2012 Elsevier Ltdpacking mediated through the N-lobe-N-lobe interactions in-
volving, in part, the P loop. The packing in the human and
murine crystals differs outside these rings. In hNIK, the C-lobes
pack together in a closed formation while in mNIK crystals, the
C-lobes also form ring-like structures. Despite sharing aspects
of crystal packing, the mNIK crystals are relatively robust both in
terms of reproducibility and diffraction, whereas humanNIK crys-
tals are difficult to reproduce and rarely diffract to better than 4 A˚.
Unphosphorylated NIK Kinase Domain Is Sufficient
for Catalytic Activity
In order to determine if the active-like conformation observed in
the crystal structures of unphosphorylated murine and human
NIK kinase domains is consistent with protein function, we devel-
oped several assays to quantify the catalytic activities of the
various NIK proteins (Table 2; Figures 3 and S2). Purified protein
used for crystallization and assays is homogenous and un-
phosphorylated as determined by mass spectrometry (data not
shown). Interestingly, autophosphorylation of NIK did not result
in increased activity in either ATPase (Figures 3A and S2A) or
kinase assays (Figures 3B and S2B). Western blotting after
incubation with ATP indicates at least some of the NIK is phos-
phorylated at Thr 559h (Figure S2A), while mass spectrometry
reveals the heterogeneous incorporation of 2–4 phosphates
per enzyme molecule. Mass spectrometry data also indicate
phosphorylation is heterogeneous with no single NIK residue
preferentially autophosphorylated (data not shown). Further,
active site titrations of several preparations of unphosphorylated
NIK protein show that the majority of the protein (typically
63%–87%) can bind and process ATP and can be inhibited byAll rights reserved
Table 2. Kinetic Parameters of NIK Protein Fragments
NIK Protein ATP Km (mM) Vmax (pmol/sec)
hNIK(327–673) lot 1 15.9 ± 0.1 1.25 ± 0.03
hNIK(327–673) lot 2 15.8 ± 2.0 0.94 ± 0.04
hNIK(327–673)-3Pi 13.8 ± 0.9 0.97 ± 0.02
hNIK(318–947) 18.3 ± 2.7 0.78 ± 0.04
hNIK(340–673) 14.9 ± 1.5 0.88 ± 0.02
mNIK(329–667) lot 1 20.6 ± 1.2 1.60 ± 0.04
mNIK(329–667) lot 2 19.2 ± 2.3 1.57 ± 0.07
hNIK(327–673) T559D 30.8 ± 2.5 0.29 ± 0.01
hNIK(327–673) T559A 17.5 ± 2.5 0.33 ± 0.01
Errors in this table are standard deviations of multiple measurements.
Structure
Structure of the NF-kB Inducing Kinasecompounds such as staurosporine that are expected to bind in
the catalytic site (Figure S2C).
Characterization of additional NIK proteins in ATP consump-
tion assays showed that neither phosphorylation nor removal
of the N-terminal helix affected the Km for ATP or the Vmax. Like-
wise, a NIK protein that includes the entire C-terminal region also
displays ATPase activity similar to the kinase domain alone (Fig-
ure 3; Table 2). To determine if the kinase domain is sufficient for
kinase activity, rather than for just uncoupled ATP hydrolysis, we
tested the phosphorylated kinase domain, the unphosphory-
lated kinase domain, and a longer protein that includes the
C-terminal region of NIK for the ability to transfer phosphate
from ATP onto peptides derived from IKKa. All of the NIK
proteins had approximately equivalent activity in these kinase
assays (Figures 3B and S2B). Intriguingly, assessment of the
ATPase activity of both theT559hD and T559hA mutants reveals
somewhat reduced activity as compared to wild-type NIK (Table
2). Thus, unphosphorylated NIK is catalytically active with
respect to both ATPase and kinase activity. Neither of these
activities is increased by NIK autophosphorylation or by intro-
duction of a phosphomimetic mutation at T559h.
Structure of mNIK with a 6-Alkynylindoline Inhibitor
Reveals a Narrow Nucleotide-Binding Site
In order to assess whether the apo form of NIK represents
a conformation that is capable of binding inhibitors, we soaked
crystals of mNIK with a NIK inhibitor (cmp1, Table 3) from the
patent literature (Chen et al., 2011). This 6-alkynylindoline
compound suppressesNIK activity in anATPconsumption assay
with a Ki of 4 nM (Table 3). Electron densitymaps calculated from
data collected on crystals of apo mNIK soaked with cmp1 re-
vealed unambiguous density for the bound inhibitor (Figure S3A)
with little change in the conformation of mNIK kinase on binding
the inhibitor (FigureS3B). TheP loop retains the irregular structure
thatmay be stabilizedby crystal-packing interactions (Figure 4A).
Within the binding site, both Arg410m and the gatekeeper
residueMet 471m adjust to create a constricted binding cleft fully
occupied by the inhibitor (Figures 4A and 4B). With cmp1 bound,
Arg 410m reorients toward solvent and the side chain adopts at
least two major conformations. Within the active site cleft, the
aminopyrimidine group of cmp1 interacts with the ‘‘hinge’’ region
between the N- and C-lobe with the amino group donating
a hydrogen bond to the backbone carbonyl of Glu472m. TheStructure 20, 1704–1pyrimidine nitrogen accepts a long hydrogen bond from the
backbone amide of Leu 474m with a heavy atom to heavy atom
distance of 3.3 A˚. The indoline group sits in the narrow space
(7 A˚ x 14 A˚ x 9 A˚) vacated by the guanidinium group of Arg
410m. The conserved residues Leu 524m and Val 416m form
a hydrophobic pinch that bracket the indoline group. The slender
alkyne occupies a constricted channel formed by the side chains
of Met 471m, Lys 431m, and Asp 536m (the D of the ‘‘DFG’’ motif).
The alkyne positions the thiazole ring of cmp1 in a small hydro-
phobic pocket behindMet 471m. The thiazole ringmakes a favor-
able edge-to-face interaction with the phenyl ring of Phe 537m. It
also makes a hydrogen bond with the backbone amide of Asp
536m. The hydroxyl group in the propargyl alcohol displaces
a water molecule observed in the crystal structure of apo murine
NIK. This hydroxyl makes polar interactions with the side chain of
Glu 442m from the aC helix and the backbone amide of Phe 537
m.
Structure of mNIK with a 2-(Aminothiazolyl)phenol
Reveals Rearrangement of the P Loop
To explore the influence of crystal-packing interactions on the
NIK P loop, we tried to find another crystal form. To achieve
this aim, a third wave of twenty-five constructs encoding
versions of murine NIK were designed as guided by the struc-
tures of the hNIK and mNIK kinase domains. These constructs
included optimized N- and C-termini to match the ordered
regions of the structures, ‘‘loop swaps’’ to replace the disor-
dered loop in the N-lobe with shorter loops, mutations designed
to reduce surface entropy (Cooper et al., 2007) and deletion of
the initial helix (residues 334m–342m) to remove a crystal-packing
contact. In total, >100 constructs were generated in several
stages for crystallization trials (Table S1). This wave approach
to cloning and expression testing allowed refinement of the
cloning strategy to include data from the earlier sets of con-
structs and structure-guided hypotheses.
One of the shorter constructs of the mNIK kinase domain
encompassing residues Gly 345m–Arg 675m (343h–673h) was
co-crystallized with a 2-(aminothiazolyl)phenol containing
compound (cmp2, Table 3) in space group C2221 and diffracted
to 1.64 A˚ (Table 1). Initial electrondensitymaps revealed thepres-
ence of cmp2 at the active site as well as dramatic changes to
the conformation of the P loop (Figures 4C, 4D, and S3C). Within
the nucleotide-binding site, changes in the conformation of
several side chains including Met 471m indicate a degree of flex-
ibility in this pocket. Outside the active site and the P loop, the
enzyme is in a largely active conformation similar to the apo
and cmp1 bound mNIK kinase domain structures (Figure 4C).
In this structure, the P loop possesses the more typical paired
beta strand conformation forming a lid over the active site (Fig-
ure 4D). The tip of the P loop shifts by8 A˚ from the apo structure
with Phe 413m from the GxGxFmotif now positioned toward Gly
538m in the DFG motif at the start of the activation loop. These
changes propagate through residues 404m–414m. For example,
the backbone of Arg 410m has moved 4.5 A˚ and reoriented
such that the side chain points away from the nucleotide-binding
site. Val408m moves by 6.5 A˚ and packs against the bound
inhibitor (Figure 4D). A recently published structure of hNIK
bound to ATPgS shows a similar but slightly more open confor-
mation of the P loop likely due to both the bound ligand and











































Figure 3. Unphosphorylated NIK Kinase Domain Is Sufficient for ATPase and Kinase Activity
(A) Plot of initial velocity versus ATP concentration for mNIK 329m–667m kinase domain in an assaymonitoring intrinsic ATPase activity. This assay used 100 nMof
NIK (wild-type proteins) or 600–700 nM NIK (mutant proteins). The Km for ATP and Vmax calculated for mNIK from this plot, as well as the kinetic constants for
additional NIK proteins, are summarized in Table 2. Vmax was normalized to 100 nM enzyme concentration.
(B) Kinase activity of NIK. The plot shows the phosphorylation of a peptide containing the Ser 176 phosphorylation site in IKKa versus NIK concentration for the
human NIK 327h–673h kinase domain (solid line), a phosphorylated hNIK 327h–673h kinase domain (dotted line), and a hNIK protein (318h–947h) that includes the
entire C terminus (dashed line). The error bars represent the standard deviation of multiple measurements. All three NIK proteins show largely equivalent ability to
phosphorylate this peptide fragment of IKKa. Supporting assay data are included in the Supplemental Experimental Procedures and Figure S2.
Structure
Structure of the NF-kB Inducing KinaseCmp2 is almost completely sequestered from solvent due
to the hydrogen bond between the carbonyl of V408m in the
P loop and the side chain of Gln 481m (Figure 4E). Cmp2 does
not make a classical donor-acceptor interaction with the
‘‘hinge.’’ Indeed, the only interaction to the hinge is a marginal
3.1 A˚ hydrogen bond between the cyano group and the
backbone amide of Leu 474m. In addition to the longer than
optimal distance, the cyano group is pointing toward the back-
bone –NH at a 140 angle instead of the optimal angle of 180.
These suboptimal interactions likely explain why a des-cyano
compound (cmp3) is equipotent to cmp2 (Table 3). The fluoro-
phenol group of cmp2 is sandwiched between the side chains
of Lys 431m and Met 471m forming favorable van der Waals
and thioether to aryl stacking. The hydroxyl group on cmp2
makes multiple polar interactions with the murine NIK protein
which are critical to binding affinity of cmp2 as a des-hydroxyl
analog is 80-fold less potent (data not shown). A comparison
of the structures of the mNIK kinase domain bound to cmp1
and cmp2 reveals that both possess hydroxyl groups that are
key to their affinities but that these hydroxyls interact with
different parts of the protein. When the respective protein
structures were superposed, the two hydroxyl groups are 1.8 A˚
apart. In addition, the thiazole ring in cmp2 occupies the same
region of space as the indoline core of cmp1, but the angle of
the ring to the protein surface differs.
The hydrophobic pocket occupied by the thiazole ring of cmp1
is less prominent when cmp2 is bound as it is partially filled due
to a change in the conformation of Met 471m and a different
rotamer of Leu 457m. The channel occupied by the alkynemoiety
in the structure with cmp2 is also less visible in the structure with
cmp2 due to a rotation of the Asp 536m carboxyl group, shifting
of the Glu 442m side chain and movement of the flexible side
chain of the Met 471m gatekeeper residue. Despite these differ-1710 Structure 20, 1704–1714, October 10, 2012 ª2012 Elsevier Ltdences, cmp1 can be successfully docked into the cmp2 protein
structure using the GOLD program (Verdonk et al., 2003), as long
as Met 471m is allowed to sample low energy conformers. The
top-scoring pose of cmp1 agrees with the structure determined
experimentally.
The V408mL Mutation ‘‘Humanizes’’ the Murine NIK
Kinase Domain
In the conformation of the P loop observed in the cmp2-mNIK
structure, Val 408m packs against the inhibitor (Figure 4E). The
presence of a larger leucine residue at this position in the hNIK
sequence may make this already constricted binding site even
smaller. To make the mNIK active site more human-like, as well
as toassess the impactof a leucineat thisposition, twoconstructs
were generated that included the V408mL mutation (Table S1).
mNIK 345m–675m V408mL was co-crystallized with a variant of
cmp2 in which the hinge-binding moiety has been replaced with
a pyridine (cmp3, Tables 1 and 3; Figures 5A and S4). Unexpect-
edly, the presence of the leucine does not constrict the active
site, but instead makes it marginally larger due to the one carbon
homologation of valine to leucine (Figure 5B). This results in an
2 A˚ difference between the location of the Cg1 in Val 408m
from Cd1 in Leu 408m. The Leu versus Val difference in human
and murine NIK may lead to differing potencies against murine
and human NIK for compounds that interact with this residue.
This hypothesis is consistent with assay data for a set of 32
varied inhibitors tested with mNIK, hNIK, and the mNIK
V408mL mutant. Some of the inhibitors inhibit murine NIK with
modestly decreased affinity as compared to human NIK (Fig-
ure 5C). This effect is variable as shown by the degree of scatter
in the points in Figure 5C. Staurosporine, which possesses
a large flat ring system that would be expected to contact Val
408m/ Leu 410h, is an example of a compound that exhibitsAll rights reserved
Table 3. Chemical Structures and Inhibition Data
Structure
Structure of the NF-kB Inducing Kinasespecies-dependence and inhibits murine NIK 5.5 fold less well
than human NIK (Figure 5C). Notably, making the V408mL muta-
tion in murine NIK largely endows mNIK with a similar inhibition
profile as hNIK (Figure 5D).DISCUSSION
Despite its importance in regulating the noncanonical NF-kB
pathway, NIK has not been well characterized enzymatically
due to challenges with expressing recombinant NIK. The cloning
and expression approach taken here involved waves of human
and murine constructs, varied ends, and point mutations result-
ing in generation of active kinase domain for structural and enzy-
matic characterization. This approach exploits high throughput
cloning and expression techniques to enable the development
of several NIK crystallization systems.
Our structural studies indicate NIK has an active confor-
mation in the absence of phosphorylation. Biochemical data
show non-phosphorylated NIK kinase domain is sufficient for
ATPase and kinase activity and that phosphorylation of NIK
does not result in increased activity. In this regard, NIK is distinct
from protein kinases such as the Cyclin-dependent kinases
(Jeffrey et al., 1995) or EGFR (Stamos et al., 2002; Zhang et al.,
2006) that require either phosphorylation and/or protein-protein
interactions to access a catalytically-competent conformation.
Inspection of the human and murine NIK structures in different
crystal-packing conditions suggests the conserved N-terminal
helix formed by residues 349h–361h orients the aC helix and other
elements in the N-lobe for catalysis (Figure 2A).
Early characterization of mutant forms of NIK in a cellular
context suggested the possibility that NIK might require phos-
phorylation for activity (Lin et al., 1998) despite being a non-RD
kinase (Johnson et al., 1996). Our enzymatic characterization
of purified recombinant NIK proteins indicate that phosphoryla-
tion does not increase NIK activity. As a non-RD kinase, NIK
lacks the arginine residue in the ‘‘HRD’’ motif (HGD in NIK, resi-
dues 513h–515h). In ‘‘RD’’ kinases such as PKA, the arginine sideStructure 20, 1704–1chain in this motif typically interacts with the phosphorylated
residue in the activation loop stabilizing the active conformation
(Figure 2D). NIK has a glycine at the central position of this
motif. Glycine lacks a side chain and is not capable of providing
either a steric or an electrostatic complement to a negatively
charged phosphate. Although our results indicate phosphoryla-
tion is not required for enzymatic activity, phosphorylation of
NIK could be important for other important processes such as
cellular localization, macromolecular substrate recognition, or
deactivation. There may be additional mechanisms of regulation
of NIK activity that involve the N-terminal region of the protein
(1h–307h), which we did not probe with the protein constructs
used here.
The observation that NIK accesses an active conformation
without phosphorylation may reflect the role of NIK in the NF-kB
pathway. In the absence of pathway activation, NIK protein is
regulated by constitutive TRAF3/cIAP-mediated ubiquitin-trig-
gered degradation (Varfolomeev et al., 2007; Zarnegar et al.,
2008a, 2008b). Upon activation of the non-canonical NF-kB
pathway, NIK degradation is blocked, allowing NIK protein to
accumulate. Theability to intrinsicallyphosphorylatedownstream
targets such as IKKawithout requiring an additional phosphoryla-
tion step may make this process more responsive to signaling
events. Other non-RD kinases such as RIP1 are also regulated
in part by ubuiqitnation. Non-RD kinases are more common in
the innate immune response, suggesting a lack of dependence
on phosphorylation of the activation loop may be an evolutionary
advantage in these pathways (Dardick and Ronald, 2006).
Structural studies also revealed that the NIK kinase domain
possesses a significant degree of conformational variability.
Two dominant conformations of the P loop have been observed
by crystallography. The conformation seen in the apo structures
of human and murine NIK may be favored by the nearby crystal-
packing interactions. Nonetheless, in order to have crystallized,
this conformation is likely present in solution at some level. The
structure of mNIK co-crystallized with 2-(aminothiazolyl)phenol
containing compounds exhibits the typical paired beta strand
P loop conformation as does a recently published structure of
hNIK bound to ATPgS (Liu et al., 2012).
Due to the importance of noncanonical NF-kB in human
disease and the critical role of NIK in regulating this pathway,
there is considerable interest in assessing the effect of inhibiting
NIK. Given the high degree of sequence similarity shared by
murine and human NIK, the two proteins might have been
expected to behave very similarly in structural and enzymatic
assays. Although the structures of the murine and human
NIK kinase domain were essentially identical, the subtle differ-
ence between Leucine (406h) in hNIK and the corresponding
Valine (408m) in mNIK can result in significantly differing affinities
of compounds for human and murine NIK. This sequence
differencemayaffect the interpretation of in vivodata frommouse
models of human diseases for some compounds. For instance,
the use of compounds that are less potent on murine NIK than
human NIK in mouse models of human diseases may lead to an
underestimation of the effect of pharmacological intervention in
the NIK axis. Thus, our data, including the systematic character-
ization of the structure and enzymatic activity of human and
murine NIK proteins, should help interrogate this pathway and























Figure 4. Structure of mNIK Bound to
Diverse Inhibitors Reveals Conformational
Plasticity
(A) Ca ribbon image of mNIK (colored as in Fig-
ure 2A) covered by a transparent surface bound to
cmp1 (carbon atoms colored magenta) showing
cmp1 is largely sequestered from solvent. The
P loop (orange) retains the conformation seen in the
structure of apo mNIK.
(B) Details of interactions cmp1 (carbon atoms
colored pink) makes with mNIK (carbon atoms
colored yellow with a transparent white surface).
Potential hydrogen bonds are shown as dashes.
Water molecules are shown as small spheres.
(C) Superposition of mNIK with cmp1 (carbon
atoms colored yellow) on mNIK bound to cmp2
(carbon atoms colored dark green) showing the
backbone conformations are very similar except
for the P loop. Cmp2 is shown as spheres with
carbon atoms colored violet.
(D) Details of the reconfiguration of the P loop and
the gatekeeper residue M417m are shown in the
superposition of the structures of mNIK bound to
cmp1 (yellow) and mNIK bound to cmp2 (green).
Additional information is included in Figure S3.
(E) Close-up of the interactions made by cmp1 with
mNIK. The mNIK protein is shown as green sticks
and a transparent white surface. Hydrogen bonds
are shown as dashed lines.
Structure
Structure of the NF-kB Inducing KinaseEXPERIMENTAL PROCEDURES
Additional details are included in the Supplemental Experimental Procedures.
Cloning, Protein Expression, and Purification
DNA encoding human and murine NIK was cloned into either a pET21b E. coli
expression vector or a modified pAcGP67 baculovirus transfer vector (BD
PharMingen). The SF9 cell line was used for insect cell expression. Insect cells
were harvested after 72 hr of growth. Soluble protein was purified by Ni-NTA
affinity and size exclusion chromatography. The His6 tag was removed from
all proteins except the crystallization sample of mNIK 345m-675m V408mL by
adding TEV protease and incubating overnight at 4C followed by removal of
the uncleaved protein by passage over an Ni-NTA column. All purified re-
combinant NIK proteins were characterized by electrospray mass spectros-
copy analysis and found to be unphosphorylated. Proteins used for assays
were formulated in 20 mM Tris-HCl (pH 8.0), 300 mM NaCl, 40% glycerol,
and 0.25 mM TCEP.
Crystallization
Apo mNIK (329m–675m) protein solution was concentrated to 9.5 mg/ml in
20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 4% glycerol, and 1 mM TCEP1712 Structure 20, 1704–1714, October 10, 2012 ª2012 Elsevier Ltd All rights reserved(Buffer B) supplemented with 1 mM of the CDK2
inhibitor NU6140 (Calbiochem). Crystals were
grown at 4C in hanging drops with a reservoir
solution of 100 mM sodium citrate tribasic dihy-
drate (pH 6.2), 0.5 M ammonium sulfate, 0.9 M
lithium sulfate and were cryoprotected in crystalli-
zation well solution plus 15% xylitol (QIAGEN
#133292) and 15% D-(+)-sucrose (QIAGEN no.
133191). Crystals of mNIK with cmp1 were ob-
tained by soaking crystals of apo mNIK in reservoir
supplemented with 1 mM cmp1 at 4C for 48 hr.
The soaked crystals were cryo protected as
for apo mNIK. Crystals of Apo hNIK 308h–673h
(7.5 mg/ml in Buffer B supplemented with 1 mM
AMP-PNP (Sigma Aldrich A2647) were grownby vapor diffusion in hanging drops at 4C over a reservoir solution of
100 mM imidazole (pH 6.5), 1.0 M sodium acetate tri-hydrate, and 7.5%
1,6-hexanediol. Crystals were dehydrated by being briefly transferred into
a drop of 100% N-Paratone prior to flash-cooling in liquid nitrogen. Crystals
of mNIK G345m-R675m (10 mg/ml in Buffer B supplemented with 1 mM
cmp2) grew in sitting drops composed of equal volumes of protein and
reservoir solution (100 mM bis-Tris (pH 6.5), 100 mM sodium chloride, 20%
PEG 4000) at 4C. Crystals were cryoprotected in reservoir solution with
10% glycerol.
Crystals of mNIK 345m–675m V408mL (6 mg/ml in Buffer B supplemented
with 0.5 mM cmp3) were grown by vapor diffusion in sitting drops composed
of 0.2 ml protein and 0.2 ml reservoir solution and incubated over a reservoir
solution of 100 mM HEPES (pH 7.0), 0.01 M zinc chloride, 20% PEG 6000 at
4C, and cryoprotected in reservoir solution with 10% glycerol. These crystals
and those of mNIK 345m–675m with cmp2 were difficult to reproduce. Crystals
grow readily in similar conditions but only rarely diffract to better than 3 A˚ at
a synchrotron.
Data Collection and Structure Determination
Diffraction data were processed and scaled with the HKL suite of programs










































hNIK log Ki (M)
Figure 5. The V408mL Mutation ‘‘Human-
izes’’ the Murine NIK Kinase Domain
(A) Structure of mNIK 345m–675m V408mL bound
to cmp3.
(B) Superposition of mNIK 345m–675m V408mL
(blue) on mNIK 345m–675m (yellow and white
transparent surface) showing the presence of a
valine in the mNIK makes the pocket slightly
smaller due to the position of the valine methyl
group.
(C) Plot of the log(Ki) for hNIK (327
h–673h) and
mNIK (329m–675m) for 32 compounds tested in
triplicate titrations in an ATPase activity assay,
including staurosporine (red square). The data are
fit with a line with R2 = 0.83, Slope = 1.01 and an
intercept of 0.37. The Ki of staurosporine for hNIK
is 15 nM and for mNIK is 83 nM based on two to
four measurements.
(D) Comparison of Ki values for hNIK (327h–673h)
and mNIK (345m–675m) V408L for the same
32 compounds. The data are fit with a line with
R2 = 0.94, slope = 1.03, and an intercept of0.067.
The Ki of staurosporine (red square) for mNIK
(345m–675m) V408mL is 4.3 nM.
See also Figure S4.
Structure
Structure of the NF-kB Inducing Kinaseset was solved by molecular replacement using the program Phaser. The
search model was a homology model of hNIK generated using PAK1
(PDB code 1YWH) and Aurora A (PDB code 1MUO) as templates. Inspection
of the initial electron density maps revealed the C-terminal lobe was
well positioned but that the N-terminal beta-sheet region was not well-placed
and required extensive rebuilding. Additional density was also apparent at
the N- and C terminus of the search model corresponding to secondary
structure elements (e.g., 334m–365m) that were not included in the homology
model. The remaining structures were solved by molecular replacement
using the apomNIK structure as the searchmodel. Cycles ofmanual rebuilding
were carried out using Coot (Emsley and Cowtan, 2004). NCS-restraints
were applied where appropriate. A consistent Rfree set was used within
each distinct crystal form. Minimal density was visible in the active site of
either the apo mNIK and apo hNIK structures despite the inclusion of
NU6140 and AMP-PNP, respectively. These compounds seem to improve
crystal growth by stabilizing the solution phase hNIK and mNIK kinase
proteins during the crystallization process. Figures were made with Pymol
(DeLano, 2002).
Assays
Pyruvate Kinase/Lactic Dehydrogenase ADP-Coupled ‘‘ATPase’’
Assay
The PK/LDH coupled assay (Barker et al., 1995) was used to quantify the
intrinsic ability of NIK enzyme samples to catalyze the hydrolysis of ATP.
Kinase Assays with Biotin-IKKa(167–189) Peptide and GST-IKKa
(165–191) Fusion Protein as Substrate
GST- and biotinylated peptides containing the activation loop sequence of
IKKa were generated for use in western blot and Alphascreen kinase assays.
Alphascreen detection of the phosphorylation of the GST-IKKa (165–191) or
biotinylated peptides relied on glutathione-coated donor or Streptavidin-
coated Alphascreen beads as appropriate (Perkin Elmer 6765300).
KinaseGlo ATP Consumption Assay for Mouse versus Human NIK Ki
Determinations
Inhibition of the hNIK, mNIK, and mNIK V408mL mutant was monitored in
reactions containing 50 mM HEPES buffer (pH 7.2), 10 mM MgCl2, 2 mM
DTT, 0.01% Triton X-100, 5 mM ATP, 7.5 to 15 nM NIK, and 0.00028–50 mMStructure 20, 1704–1714, October 10, 2012 ªinhibitor in 2% DMSO. Ki values were determined
in three separate experiments with duplicate
inhibitor titrations by fitting to the Morrisontight-binding inhibition equation for competitive inhibition (Williams and
Morrison, 1979). Correlation plots of the Ki values between enzyme forms
were generated using KaleidaGraph v. 4.03 software (Synergy Software,
Reading, PA).
Chemical Syntheses
Cmp1 was synthesized as described in the patent literature (Chen et al., 2011).
Cmp2 and cmp3 originated from a high throughput screen of the Genentech
chemical library followed by limited chemical optimization. Details of the
synthesis and chemical structure determination of each compound are
included in the Supplemental Experimental Procedures.
ACCESSION NUMBERS
The coordinates and structure factors have been deposited in the Protein Data
Bank under the accession codes 4G3C (apo mNIK), 4G3D (apo hNIK), 4G3E
(mNIK-cmp1), 4G3F (mNIK-cmp2), and 4G3G (mNIK-cmp3).
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Supplemental Information includes one table, four figures, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.str.2012.07.013.
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